Many blood cancers are driven by cancer stem cells, which are responsible for disease relapse and drug resistance. Unfortunately, a cancer cell line only represents a single clone and does not capture the hierarchy and complex differentiation pattern of human cancer. Our HuKemiaÒ platform consists of two main components:
Ex vivo HuKemia®: Compound activity profiling in primary patient cancer cells
This platform takes the advantage of our access to primary cancer cells and tissues, and uses them directly for ex vivo compound activity profiling. In addition to its ability to reflect individual patient disease biology, the assay format enables a broad survey of drug response in a diverse patient population, which would be otherwise impractical with in vivo animal models.
In vivo HuKemia®: Compound activity evaluation in models established from primary patient cancer cells
The in vivo models are established by serial transplantation of primary patient cancer tissues (i.e. bone marrow or peripheral blood) in immune-deficient mice, and have similar disease manifestation in mice to that in human. These models provide a unique opportunity for companies interested in target discovery and validation, and evaluating drug response in a clinically relevant model. Our library of HuKemiaÒ models include:
- Acute lymphocytic leukemia (ALL) model view data 1, 2
- Non-Hodgkin's lymphoma (NHL) model view data 1
